Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
Go back to Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million| (NASDAQ: DNLI) | Delayed: 20.13 +0.07 (0.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.06 | 52 Week High | $ | |||
| Open | $20.57 | 52 Week Low | $ | |||
| Day High | $20.65 | P/E | N/A | |||
| Day Low | $19.90 | EPS | $ | |||
| Volume | 1,421,393 | |||||
